Moleculin Advances AML Treatment with Positive FDA Feedback and Plans for Phase 3 MIRACLE Trial
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, has made significant strides in the development of treatments for hard-to-treat tumors and viruses, particularly in the area of relapsed or refractory acute myeloid leukemia (R/R AML). The company recently reported a positive outcome from its End of Phase 1B/2 meeting with the US Food and Drug Administration (FDA), which supports the advancement of Annamycin in combination with cytarabine (AnnAraC) to a Phase 3 pivotal trial for R/R AML patients.
-
MIRACLE Trial: The upcoming Phase 3 trial, named MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation), is designed for possible accelerated approval of Annamycin in combination with cytarabine. This global trial will include sites in the US and is expected to utilize an adaptive design to determine the optimum dose of Annamycin.
-
Clinical Achievements: The company has reported additional positive efficacy findings from its Phase 1B/2 clinical trial evaluating AnnAraC for the treatment of AML. Notably, a significant percentage of subjects achieved complete remission (CR) or complete remission with incomplete recovery of peripheral blood counts (CRi), demonstrating the potential of AnnAraC as a treatment for R/R AML.
-
Financial Results: For the second quarter of 2024, Moleculin reported research and development expenses of $4.1 million, a slight increase from the previous year, primarily due to sponsored research costs. The company also noted a decrease in general and administrative expenses, attributed to lower regulatory and legal fees. With $10.8 million in cash and cash equivalents as of June 30, 2024, Moleculin is confident in its financial position to fund operations into the fourth quarter of 2024, with plans to raise additional funds.
-
Future Milestones: Key upcoming milestones include beginning contracting with MIRACLE trial sites in the second half of 2024, treating the first subject in the MIRACLE trial by the first quarter of 2025, and setting the optimum dose for Annamycin by mid-2026. The company aims to submit a new drug application for accelerated approval of Annamycin for R/R AML treatment by the second half of 2028.
Moleculin's progress in the development of Annamycin, combined with its strategic planning and financial management, positions the company as a promising player in the fight against R/R AML and other challenging diseases.